{"id":"lipofundin-mct-20","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertriglyceridemia"},{"rate":null,"effect":"Infusion site reactions (phlebitis, thrombophlebitis)"},{"rate":null,"effect":"Hypersensitivity reactions"},{"rate":null,"effect":"Hepatic dysfunction"},{"rate":null,"effect":"Pancreatitis"}]},"_chembl":{"chemblId":"CHEMBL5566852","moleculeType":null,"molecularWeight":"1824.25"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This intravenous lipid emulsion contains a mixture of medium-chain triglycerides (MCT) and long-chain triglycerides (LCT) that serve as an energy source and provide essential polyunsaturated fatty acids. It is administered as part of total parenteral nutrition (TPN) to support metabolic needs, maintain nutritional status, and prevent essential fatty acid deficiency in critically ill or post-operative patients.","oneSentence":"Lipofundin MCT 20% is a lipid emulsion that provides essential fatty acids and calories for parenteral nutrition in patients unable to eat or absorb nutrients orally.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:40:53.959Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parenteral nutrition in patients unable to maintain adequate oral or enteral intake"},{"name":"Prevention of essential fatty acid deficiency during prolonged parenteral nutrition"},{"name":"Nutritional support in post-operative and critically ill patients"}]},"trialDetails":[{"nctId":"NCT03282955","phase":"PHASE4","title":"The HOME Study (HPN With OMEGA-3)","status":"COMPLETED","sponsor":"B. Braun Melsungen AG","startDate":"2018-01-08","conditions":"Patients Requiring Home Parenteral Nutrition","enrollment":74},{"nctId":"NCT00497289","phase":"PHASE2","title":"Comparison of Two Different Lipid Emulsions for Parenteral Nutrition in Preterm Infants","status":"COMPLETED","sponsor":"B. Braun Melsungen AG","startDate":"2006-01","conditions":"Preterm Infants, Parenteral Nutrition n-3 Fatty Acids","enrollment":48},{"nctId":"NCT04511299","phase":"NA","title":"Impact of Fish Oil-enriched Lipid Emulsion on Fatty Acid and Inflammatory Response in Infants After Surgery","status":"COMPLETED","sponsor":"Dr. Soetomo General Hospital","startDate":"2020-04-07","conditions":"Surgery","enrollment":12},{"nctId":"NCT04347902","phase":"PHASE4","title":"Lipid Emulsions and Liver Function - Results After 5 Years.","status":"COMPLETED","sponsor":"Stanley Dudrick's Memorial Hospital","startDate":"2016-01","conditions":"Liver Failure, Parenteral Nutrition-Related Hepatitis","enrollment":65},{"nctId":"NCT01814956","phase":"PHASE4","title":"Different Lipid Emulsions in Acute Lung Injury Patients","status":"TERMINATED","sponsor":"B. Braun Melsungen AG","startDate":"2013-03","conditions":"Parenteral Nutrition","enrollment":1},{"nctId":"NCT01745861","phase":"PHASE2","title":"Effects Of Fish Oil Emulsion On Severe Acute Pancreatitis Patients","status":"COMPLETED","sponsor":"University Hospitals, Leicester","startDate":"2010-06","conditions":"Assess Effect of Omega-3 Fish Oil in Patients With Severe Acute Pancreatitis","enrollment":44},{"nctId":"NCT01025414","phase":"PHASE4","title":"Enteral Nutrition in the Treatment of Pancreatic Fistulas - A Prospective Study","status":"COMPLETED","sponsor":"Jagiellonian University","startDate":"2006-07","conditions":"Pancreatic Fistula","enrollment":78},{"nctId":"NCT00558155","phase":"PHASE4","title":"The Impact of Immunostimulating Nutrition on the Outcome of Surgery","status":"COMPLETED","sponsor":"Jagiellonian University","startDate":"2001-06","conditions":"Gastric Cancer, Pancreatic Cancer","enrollment":214}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Lipofundin MCT 20%","genericName":"Lipofundin MCT 20%","companyName":"B. Braun Melsungen AG","companyId":"b-braun-melsungen-ag","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lipofundin MCT 20% is a lipid emulsion that provides essential fatty acids and calories for parenteral nutrition in patients unable to eat or absorb nutrients orally. Used for Parenteral nutrition in patients unable to maintain adequate oral or enteral intake, Prevention of essential fatty acid deficiency during prolonged parenteral nutrition, Nutritional support in post-operative and critically ill patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}